
Gene therapy landmark in haemophilia B
Following the news that the first patients in Denmark with haemophilia B had been treated with Hemgenix (etranacogene dezaparvovec) gene therapy since European Commission approval, DDW’s Megan Thomas spoke with Dr Fredrik Sjöö, Head of Medical Affairs in the Nordic Region at CSL Behring, as well as Radovan Tomic, Global Market Access Director… Read More















